Novo Nordisk faces challenges but its pipeline remains strong. Find out why NVO stock could deliver high double-digit returns ...

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

Bernstein analysts led by Florent Cespedes increased their price target on Novo Nordisk (NOVOB:DC) (NYSE: NYSE:NVO) stock to DKK620.00, up from DKK600.00, while maintaining a Market Perform rating.

Novo Nordisk boasts 45 million customers using its drug, which has caused a revolution in weight-loss treatment. But competitors are nipping at its heels.

Morgan Stanley (NYSE:MS) initiated coverage on shares of Novo Nordisk (NOVOB:DC) (NYSE: NYSE:NVO), a global healthcare company specializing in diabetes care and other serious chronic conditions. The ...

Under the programm Bagsværd, Denmark, 24 January 2025 – Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor ...

Novo Nordisk boasts 45 million customers using their drug Ozempic, which has caused a revolution in weight-loss treatment.

Novo Nordisk's obesity therapy Wegovy put in another ... obesity candidates CagriSema (cagrilintide and semaglutide) and amycretin. In December, an initial readout from CagriSema's phase 3 ...

Data on the subcutaneous version of amycretin is due next year, and Novo Nordisk also presented early data on another oral therapy, CBR1 inverse agonist monlunabant (INV-202), which showed a 3% ...

The stock climbed 5.9% in early trading, making it the top performer on the FTSE 100 and on track for its biggest one-day gain since… February 5, 2025 Novo Nordisk shares surge as Wegovy sales ...